PNU-159682
| CAS No. | 202350-68-3 | Cat. No. | BCP13117 |
| Name | PNU-159682 | ||
| Synonyms | PNU159682;PNU 159682; | ||
| Formula | C32H35NO13 | M. Wt | 641.62 |
| Description | in vitro: The cytotoxicity of PNU-159682 were in the subnanomolar range (0.07-0.58 nmol/L) and noticeably lower than that recorded for both MMDX and doxorubicin; PNU-159682 was 2,360- to 790-fold and 6,420- to 2,100-fold more potent than MMDX and doxorubicin, respectively . in vivo: An evaluation of the in vivo antitumor activity of PNU-159682, in comparison with that of MMDX, was then conducted in mice bearing disseminated murine L1210 leukemia. Preliminary toxicity dose-finding studies showed that 15 Ag/kg i.v. was the single-dose maximum tolerated dose of PNU-159682 [1]. Several patents reported that PNU-159682 can be used as cytotoxin in ADCs design. | ||
| Pathways | Others Pathway | ||
| Targets | ADC Related | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.